Responses
IGCS meeting abstracts
Plenary sessions
Plenary 1
IGCS19-0523
1 MILO/ENGOT-OV11: Phase-3 study of binimetinib versus physician’s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
Compose a Response to This Article
Other responses
No responses have been published for this article.